Quick charity verification for Epilepsy Study Consortium Inc (EIN: 204950952)
Verdict: Epilepsy Study Consortium Inc appears trustworthy
92/100Mission Score
$2.5MRevenue
$3.7MAssets
0Red Flags
5Strengths
No red flags identified.
Strengths
Strong financial health with consistent asset growth, reaching $3,454,178 in 2023.
No reported liabilities across all 13 IRS 990 filings, indicating excellent financial stability.
0% officer compensation reported in all filings, suggesting efficient use of funds for mission-related activities.
Significant surplus in the latest fiscal year (2023), with revenue of $3,371,798 exceeding expenses of $1,701,465.
Consistent filing of IRS 990s over 13 periods, demonstrating a commitment to transparency.
Spending Breakdown
How Epilepsy Study Consortium Inc allocates its funds across programs, administration, and fundraising.
90%
Program Spending
Healthy — majority goes to mission
10%
Admin Costs
Reasonable — admin costs in check
0%
Fundraising
Within typical range
How to read this: Well-run charities typically spend 75% or more on programs, keep admin under 25%, and fundraising under 15%. A high program ratio means more of every dollar goes directly to the mission.
How to Interpret This Report
What Red Flags Mean
Red flags are potential warning signs identified by AI analysis of IRS 990 filings. They may indicate issues like declining revenue, high executive pay relative to program spending, lack of transparency, or governance concerns. A single red flag does not necessarily mean an organization is untrustworthy, but multiple flags warrant further investigation before donating.
What Mission Score Measures
The Mission Score (0-100) evaluates how effectively a nonprofit fulfills its stated purpose. It combines multiple factors: program spending efficiency (how much goes to programs vs. overhead), financial health and sustainability, governance quality, transparency in reporting, and consistency of operations over time. A score of 70+ indicates strong alignment with the organization’s mission.
Using This Data for Donation Decisions
Use this report as one input in your decision. Look at the overall Mission Score for a quick assessment, review red flags and strengths for specific concerns, check the spending breakdown to see where money goes, and compare executive compensation to the organization’s size. Consider viewing the full transparency report for deeper analysis, and always verify tax-exempt status with the IRS before making large donations.
Frequently Asked Questions about Epilepsy Study Consortium Inc
Is Epilepsy Study Consortium Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, Epilepsy Study Consortium Inc (EIN: 204950952) appears trustworthy. Mission Score: 92/100. 0 red flags identified, 5 strengths noted.
Is Epilepsy Study Consortium Inc a good charity to donate to?
Epilepsy Study Consortium Inc has a Mission Score of 92/100. Revenue: $2.5M. Assets: $3.7M. Review the full transparency report for detailed spending breakdown and executive compensation analysis.
What is the EIN for Epilepsy Study Consortium Inc?
The Employer Identification Number (EIN) for Epilepsy Study Consortium Inc is 204950952. This is the unique tax ID assigned by the IRS.
What is a Mission Score?
The Mission Score is a 0-100 rating that measures how effectively a nonprofit fulfills its stated mission. It factors in program spending efficiency, financial transparency, governance practices, and outcome reporting. Scores above 70 indicate strong mission alignment, 40-69 suggest mixed performance, and below 40 signals potential concerns.
How does Epilepsy Study Consortium Inc spend its money?
Epilepsy Study Consortium Inc allocates 90% to programs, 10% to administration, and 0% to fundraising. Healthy nonprofits typically spend 75%+ on programs.
How can I verify Epilepsy Study Consortium Inc's tax-exempt status?
You can verify Epilepsy Study Consortium Inc's tax-exempt status using EIN 204950952 on the IRS Tax Exempt Organization Search (TEOS) at apps.irs.gov/app/eos. You can also request copies of their Form 990 directly from the organization, as they are required by law to provide them upon request.
AI Transparency Report
Epilepsy Study Consortium Inc demonstrates a generally healthy financial position, with recent revenue growth and a strong asset base. In 2023, the organization reported revenue of $3,371,798 against expenses of $1,701,465, indicating a significant surplus. This positive trend follows a period of more balanced revenue and expenses in 2022 ($2,128,414 revenue vs. $1,917,817 expenses). The organization's assets have also shown consistent growth, reaching $3,454,178 in 2023, with no reported liabilities across all available filings, which is a strong indicator of financial stability and responsible management. The consistent reporting of 0% officer compensation across all filings suggests a volunteer-led or externally compensated leadership structure, which can be a positive sign for donor confidence regarding administrative costs.
Spending efficiency appears robust, particularly in the latest fiscal year where expenses were significantly lower than revenue. While a detailed breakdown of program, administrative, and fundraising expenses isn't provided in the summary data, the overall financial health suggests that the organization is effectively managing its resources. The absence of liabilities further reinforces its sound financial practices. The consistent filing of IRS Form 990s over 13 periods demonstrates a commitment to transparency, allowing public scrutiny of its financial operations.
Overall, Epilepsy Study Consortium Inc appears to be a financially stable and well-managed organization. Its ability to generate surpluses, grow assets, and maintain zero liabilities, coupled with consistent public filings and no reported officer compensation, paints a picture of a responsible and efficient nonprofit. Donors can have reasonable confidence in the organization's financial stewardship.